Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

72P - Role of pyruvate carboxykinase 2 upregulation in group 3 medulloblastoma: Implications for metabolic reprogramming and therapeutic strategies

Date

04 Oct 2023

Session

Cocktail & Poster Display session

Presenters

MEDHA GAYATHRI PAI

Citation

Annals of Oncology (2023) 8 (suppl_1_S5): 1-55. 10.1016/esmoop/esmoop101646

Authors

M.G.J. PAI1, N. Shirsat2, S. Srivastava3

Author affiliations

  • 1 Biosciences And Bioengineering Department, IIT Bombay - Indian Institute of Technology Bombay, 400076 - Mumbai/IN
  • 2 BKL Walawalkar Hospital, Diagnostic & Research Centre, 415606 - Ratnagiri/IN
  • 3 IIT Bombay - Indian Institute of Technology Bombay, 400076 - Mumbai/IN

Resources

This content is available to ESMO members and event participants.

Abstract 72P

Background

Group 3 Medulloblastoma (MB) is a subgroup of MB with poor prognosis and high chances of recurrence. The highly aggressive nature of this paediatric brain tumor necessitates targeted therapeutic approaches to improve patient outcomes. Phosphoenolpyruvate carboxykinase plays a crucial role in gluconeogenesis by catalyzing the conversion of oxaloacetate to phosphoenolpyruvate. PCK2 is the mitochondrial counterpart of this enzyme, helping in replenishment of various metabolic intermediates and hence acting as a pivotal protein between pyruvate metabolism, TCA cycle and gluconeogenesis. Recent proteomic studies on Medulloblastoma (MB) suggest extensive metabolic rewiring in Group 3 MB.

Methods

Analysis of publicly available omics data on Medulloblastoma was performed to identify the expression levels of proteins related to key metabolic pathways like Krebs cycle, pyruvate metabolism and glucose metabolism including PCK2. Key proteins belonging to these pathways were analysed in FFPE tissues from MB patients and compared with other subgroups using multiple reaction monitoring. PCK2 was knocked down in Group 3 cell lines using shRNA and evaluated for effects on proliferation and survival using culture based in vitro assays. High resolution label free proteomic analysis was performed to ascertain the effects of PCK2 knockdown.

Results

Data mining and repository data analysis found dysregulation of key proteins and metabolites. Key proteins involved in energy metabolism including PCK2 showed upregulation even at the transcriptomic level. Proteomic analysis on few FFPE samples could validate these findings. shRNA based PCK2 knockdown resulted in lowering the proliferation rates of Group 3 cells and significant changes in their proteomes.

Conclusions

The overexpression of PCK2 is involved in the aggressiveness of Group 3 MB and can be a possible target for this subset of medulloblastoma patients.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

IIT Bombay.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.